BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.820
-0.160 (-4.02%)
At close: Aug 1, 2025, 4:00 PM
3.870
+0.050 (1.31%)
After-hours: Aug 1, 2025, 4:00 PM EDT

Chimerix Stock Forecast

Stock Price Forecast

The 2 analysts that cover Chimerix stock have a consensus rating of "Strong Buy" and an average price target of $19, which forecasts a 397.38% increase in the stock price over the next year. The lowest target is $12 and the highest is $26.

Price Target: $19.00 (+397.38%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$12$19$26$26
Change+214.14%+397.38%+580.63%+580.63%
* Price targets were last updated on Jun 17, 2025.

Analyst Ratings

The average analyst rating for Chimerix stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy221222
Buy000000
Hold001000
Sell000000
Strong Sell000000
Total222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$26
Strong BuyReiterates$26+580.63%Jun 17, 2025
Jones Trading
Jones Trading
Strong Buy
Upgrades
$12
Strong BuyUpgrades$12+214.14%May 30, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$26
Strong BuyReiterates$26+580.63%May 28, 2025
Jones Trading
Jones Trading
Hold
Downgrades
n/a
HoldDowngradesn/an/aApr 2, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$9$26
Strong BuyMaintains$9$26+580.63%Mar 31, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.